Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 274
  • Home
  • Print this page
  • Email this page
Cover page of the Journal of Health Sciences
Year : 2021  |  Volume : 14  |  Issue : 3  |  Page : 356-364

Ondansetron in combination with fluoxetine for obsessive–compulsive disorder: A randomized, double-blind, placebo-controlled study from North India

1 Private Practice, King George's Medical University, Lucknow, Uttar Pradesh, India
2 Department of Pharmacology, King George's Medical University, Lucknow, Uttar Pradesh, India
3 Department of Psychiatry, King George's Medical University, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Bandna Gupta
Department of Psychiatry, King George's Medical University, Lucknow, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/kleuhsj.kleuhsj_29_21

Rights and Permissions

BACKGROUND: A large percentage of patients with obsessive–compulsive disorder (OCD) do not respond to first-line medications. Ondansetron, a 5-HT3 receptor antagonist, has been shown to be effective in the treatment of OCD as an augmentation agent to selective serotonin reuptake inhibitors. However, scientific evidence in this regard is limited. AIMS: This study aimed to study the effect of ondansetron in combination with fluoxetine on psychopathology, functioning, and quality of life in patients with obsessive–compulsive disorder and to compare these parameters with patients treated with fluoxetine alone. METHODS: This was a 12-week prospective, randomized, double-blind, placebo-controlled study. Patients fulfilling diagnostic criteria for OCD on the basis of the International Classification of Diseases 10-DCR and having a score of ≥4 clinical global impression-severity (CGI-S) were enrolled in the study. The patients received either fluoxetine with Ondansetron (4 mg/day in two divided doses) or fluoxetine with placebo randomly for a period of 12 weeks. The patients were assessed using the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS), Social and Occupational Functioning Assessment Scale, CGI, WHO Quality of Life-BREF, and an adverse event checklist at baseline and at weeks 4, 8, and 12. Seventy patients completed the study. Results: The Y-BOCS total score, obsession subscale score, and compulsion subscale score showed a significantly greater reduction in the ondansetron group than in the placebo group. Improvement in functioning and quality of life was significantly higher in ondansetron group than in placebo group. There was no statistically significant difference between the two groups in terms of side effects. Conclusion: A significant beneficial effect of combining ondansetron to fluoxetine in patients with OCD was observed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal